Cancer research saves lives and leads to improved outcomes for patients. But federal cancer research funding may be in jeopardy for 2026.

Background: Mantle Cell Lymphoma (MCL) is generally treated with rituximab (R) in combination with other drugs. However, treatment for relapsed or refractory (RR) MCL is challenging. For Ibrutinib ...